PACS Group CEO Jason Hulse Murray sells $10.4m in stock
Jason Hulse Murray, CEO of PACS Group, Inc., sold over $10.4 million worth of company stock between August 17 and August 19, 2026, through a pre-arranged trading plan. Despite these sales, Murray still directly holds a significant number of shares, and analysts maintain an optimistic outlook on PACS Group with potential upside. The company also recently announced a major acquisition of 34 skilled nursing facilities and received a "Buy" rating from Truist Securities.
PACS Group CEO Jason Hulse Murray sells $10.4m in stock
PACS Group, Inc. CEO Jason Hulse Murray sold 236,116 shares of common stock for over $10.4 million between August 17 and August 19, 2026, under a pre-arranged trading plan. Despite the insider sale, analysts maintain an optimistic outlook on PACS, with price targets suggesting a potential upside of approximately 36%. The company also recently announced the acquisition of 34 skilled nursing facilities, significantly expanding its presence in the healthcare sector.
Insider Selling: PACS Group (NYSE:PACS) CEO Sells $2,951,091.46 in Stock
PACS Group CEO Jason Hulse Murray recently sold 66,797 shares of the company's stock for $2.95 million, following a pre-arranged Rule 10b5-1 plan. This sale is part of a larger series of transactions, bringing his total recent sales to nearly $10.44 million, though he still retains a significant stake valued at $2.43 billion. The company reported strong quarterly earnings, beating analyst estimates, and maintains a "Buy" consensus rating from analysts with an average price target of $56.
Insider Selling: PACS Group (NYSE:PACS) CEO Sells 84,717 Shares of Stock
PACS Group CEO Jason Hulse Murray sold 84,717 shares of the company's stock for approximately $3.75 million on August 19th, as part of a pre-arranged trading plan, reducing his position by 0.15%. This sale follows earlier transactions in the same week. The company recently reported strong quarterly results, beating EPS and revenue estimates, and has a consensus "Buy" rating from analysts with an average target price of $56.
PACS Group (NASDAQ: PACS) CEO sells shares in 3-day preset plan
Murray Jason Hulse, Co-Founder, CEO, and Chairman of PACS Group, Inc. (NASDAQ: PACS), sold a total of 236,116 common stock shares between August 17 and 19, 2026. These sales were conducted on the open market under a Rule 10b5-1 trading plan established on May 18, 2026, with weighted average prices ranging from approximately $42.81 to $44.86 per share. Following these transactions, Hulse directly holds 54,845,416 shares of common stock.
Amid Legal Risks, This Company Is Still Rated a Buy
PACS Group's stock has made a significant comeback, with analysts rating it a "Buy" despite unresolved legal and regulatory risks. The company's recent strong Q2 financial results, including increased revenue and adjusted EPS, led to raised full-year guidance and analyst upgrades. However, ongoing Department of Justice and SEC investigations into alleged Medicare billing fraud and a securities fraud lawsuit still pose substantial uncertainties for investors.
PACS Group, Inc. SEC Filing (Aug 17, 2026)
This article details an SEC Form 144 filing by PACS Group, Inc. on August 17, 2026, which indicates a proposed sale of 386,666 shares of common stock with an aggregate market value of $16,893,437.54 through UBS Financial Services, Inc. These shares were acquired on April 11, 2024, as founders' shares from the issuer. The filing includes standard SEC disclaimers and provides information about the securities to be sold and the acquisition details.
Does PACS Group’s (PACS) Higher 2026 Revenue Guidance Reframe Its Growth And Margin Trade-offs?
PACS Group reported strong Q2 2026 results with increased revenue and net income, leading to an upgraded full-year 2026 revenue guidance of US$5.75 billion to US$5.85 billion. This higher guidance supports near-term growth, but the company's investment narrative remains centered on its ability to convert revenue momentum into sustained margin improvement, especially given its dependence on Medicaid reimbursement rates. Investors are encouraged to explore various viewpoints to assess the stock's earnings resilience and fair value.
Does PACS Group’s (PACS) Higher 2026 Revenue Guidance Reframe Its Growth And Margin Trade-offs?
PACS Group reported strong Q2 2026 results and raised its full-year 2026 revenue guidance to US$5.75 billion to US$5.85 billion. This update supports near-term growth but highlights the ongoing dependence on Medicaid rate structures and quality incentives, which could impact margins. The article encourages investors to analyze various perspectives on the company's earnings resilience and fair value.
Understanding Momentum Shifts in (PACS)
This article analyzes momentum shifts for Pacs Group Inc. (NASDAQ: PACS), highlighting weak near-term sentiment but long-term strength. It details institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis to guide investors on support and resistance levels.
Insider Selling: PACS Group (NYSE:PACS) COO Sells $1,823,600.00 in Stock
PACS Group COO Joshua Jergensen sold 40,000 shares of company stock for $1.82 million under a pre-arranged Rule 10b5-1 trading plan, reducing his ownership by 1.55%. Despite this insider selling, analysts maintain a "Buy" rating for PACS Group with a consensus price target of $56.00, following strong quarterly earnings that exceeded estimates.
PACS Group (PACS) President & COO sells 40,000 shares in Rule 10b5-1 trades
Joshua Jergensen, President & COO of PACS Group, Inc. (PACS), sold 40,000 shares of common stock on August 12, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales occurred in two transactions at weighted average prices of $44.5299 and $45.6981 per share, totaling approximately $1.82 million. Following these transactions, Jergensen directly holds 2,536,320 shares of common stock.
PACS Group (NYSE:PACS) Raised to "Strong-Buy" at Zacks Research
Zacks Research has upgraded PACS Group (NYSE:PACS) from a "hold" to a "strong-buy" rating. This upgrade follows a period where PACS Group reported strong quarterly earnings of $0.63 per share and revenue of $1.43 billion, both exceeding analyst expectations. Despite some insider selling, the company has a consensus "buy" rating with a target price of $56.00 among analysts.
PACS Group (NYSE:PACS) Trading Down 6.4% - What's Next?
PACS Group (NYSE:PACS) saw its stock price drop by 6.4% on Tuesday, with trading volume significantly lower than average. Despite the dip, analysts generally maintain a "Moderate Buy" rating for the company, with several firms recently raising their price targets. The company recently exceeded quarterly earnings and revenue expectations, though insider selling accounted for approximately $31.6 million in stock transactions during the last quarter.
PACS Group, Inc. $PACS Shares Sold by Janus Henderson Group PLC
Janus Henderson Group PLC significantly reduced its stake in PACS Group, Inc. by 90.1% in the first quarter, selling 192,970 shares. Despite this, other institutions like Millennium Management increased their holdings, and company insiders sold a substantial number of shares, though still retaining a large ownership percentage. Analyst sentiment remains positive with a "Moderate Buy" rating and an average price target of $56, following PACS Group's recent earnings beat.
PACS Group (NYSE:PACS) Price Target Raised to $57.00 at Oppenheimer
Oppenheimer has increased its price target for PACS Group (NYSE:PACS) to $57.00 from $48.00, maintaining an "outperform" rating, which suggests a potential upside of 17.27%. This follows PACS Group's strong quarterly earnings, where it surpassed analyst expectations with an EPS of $0.63 and revenue of $1.43 billion. Despite recent insider selling, the company holds a "Moderate Buy" consensus rating among analysts with an average target price of $56.00.
Oppenheimer Adjusts Price Target on PACS Group to $57 From $48, Keeps Outperform Rating
Oppenheimer has increased its price target for PACS Group (PACS) to $57 from $48, while maintaining an "Outperform" rating on the stock. This adjustment reflects continued analyst confidence in the company's performance. The article also highlights recent price target adjustments from other firms like UBS, RBC, and Truist, all revising their targets upwards and largely maintaining positive ratings, following PACS Group's Q2 2026 earnings report which showed increased adjusted earnings and revenue.
PACS Group (PACS) Is Up 5.3% After Raising 2026 Revenue Outlook On Strong Q2 Results
PACS Group (PACS) recently reported strong Q2 2026 results, with revenue rising to US$1,428 million and net income at US$76.37 million, leading to an upward revision of its full-year 2026 revenue guidance to US$5.75 billion to US$5.85 billion. The company attributes this success to high occupancy levels exceeding 90% and strategic acquisitions, reinforcing its "locally led, centrally supported" model. Investors are now focused on how quickly new facilities will contribute to revenue and EBITDA, with fair value estimates suggesting a significant upside to its current price despite integration risks.
PACS Group Q2 Earnings Call Highlights
PACS Group reported strong Q2 2026 results, with revenue growth of 9.1% and adjusted EBITDA growth of 25%, primarily driven by its existing portfolio. The company highlighted improved occupancy, skilled nursing patient mix, and quality metrics across its facilities. PACS also detailed its re-entry into a more active acquisition period with the Eduro Healthcare deal and raised its full-year 2026 revenue and adjusted EBITDA guidance.
PACS Group Q2 Earnings Call Highlights
PACS Group reported strong Q2 2026 financial results with revenue up 9.1% to $1.43 billion and adjusted EBITDA up 25%. The company's growth was driven by existing facilities, with improvements in same-store occupancy and skilled patient mix. PACS also raised its full-year 2026 revenue guidance to $5.75 billion-$5.85 billion and adjusted EBITDA guidance to $640 million-$660 million, following the acquisition of 20 Eduro Healthcare facilities and expectations for 14 more.
PACS Group Q2 Earnings Call Highlights
PACS Group reported strong Q2 2026 results with 9.1% revenue growth and 25% adjusted EBITDA growth, driven by higher occupancy and improved skilled nursing patient mix. The company also raised its full-year 2026 revenue guidance to $5.75 billion to $5.85 billion and adjusted EBITDA guidance to $640 million to $660 million. Additionally, PACS detailed the successful turnaround of a California behavioral-health facility and its active acquisition period, including the ongoing integration of Eduro Healthcare facilities.
PACS Group (NYSE:PACS) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded PACS Group (NYSE:PACS) from "strong-buy" to "buy," though the average analyst rating remains a "Moderate Buy" with a $54.20 price target. The company exceeded quarterly earnings expectations, reporting $0.63 EPS against a $0.54 consensus and $1.43 billion in revenue. Despite recent insider selling, PACS Group stock rose 3.7% and several institutional investors increased their positions.
PACS Group (PACS) Is Up 5.3% After Raising 2026 Revenue Outlook On Strong Q2 Results
PACS Group's stock rose 5.3% after reporting strong Q2 2026 results, with revenue reaching US$1,428 million and net income US$76.37 million. The company subsequently raised its full-year 2026 revenue guidance to US$5.75 billion to US$5.85 billion, citing occupancy levels above 90% and ongoing facility acquisitions. This positive outlook reinforces the company's growth strategy, though integration risks from recent acquisitions remain a key concern for investors.
PACS Group (PACS) Is Up 5.3% After Raising 2026 Revenue Outlook On Strong Q2 Results
PACS Group (NYSE: PACS) saw its stock rise by 5.3% after reporting strong Q2 2026 results, including increased revenue and net income, and subsequently raising its full-year 2026 revenue guidance. The company highlighted high occupancy levels and plans for further acquisitions, reinforcing its growth strategy. Investors are encouraged to consider the company's detailed financial analysis and fair value estimates.
Cohen & Steers (PACS) reports 4.67% beneficial stake in PACS Group
Cohen & Steers and its affiliates have reported a beneficial ownership of 4.67% in PACS Group, Inc. common stock, totaling 7,396,136 shares. This filing, a SCHEDULE 13G/A, indicates that their stake is below the 5% threshold typically referenced for significant holders. The various Cohen & Steers entities hold these securities for the benefit of their account holders, who retain rights to dividends and sale proceeds.
PACS Group Inc stock hits all-time high of 48.23 USD
PACS Group Inc. stock has reached an all-time high of $48.23, reflecting a significant 318.12% increase over the past year. The company reported strong financial results for Q1 2026, surpassing earnings expectations and announcing the acquisition of 34 skilled nursing facilities. Despite an InvestingPro analysis suggesting the stock might be overvalued, Truist Securities reiterated a Buy rating with a $52.00 price target.
Dimensional Fund Advisors LP Acquires 614,250 Shares of PACS Group, Inc. $PACS
Dimensional Fund Advisors LP significantly increased its stake in PACS Group, Inc. (NYSE:PACS) by 370.2% in the first quarter, purchasing 614,250 additional shares to hold a total of 780,159 shares valued at approximately $25.1 million. Other institutional investors also expanded their positions in PACS Group. The company has a "Moderate Buy" consensus from analysts with an average price target of $50.60, following strong Q1 earnings where it surpassed revenue and EPS expectations.
Analysts Offer Insights on NA Companies: PACS Group Inc (PACS) and SpaceX (SPCX)
Analysts from Truist Financial and Macquarie have issued bullish sentiments on PACS Group Inc (PACS) and SpaceX (SPCX) respectively. David S Macdonald of Truist Financial maintained a Buy rating on PACS with a consensus price target of $51.00, while Paul Golding of Macquarie also maintained a Buy rating on SpaceX with an average price target of $228.18. Both companies show significant upside potential according to these analyst reports.
PACS Group Inc stock hits all-time high of 48.23 USD
PACS Group Inc. stock has reached an all-time high of $48.23, now trading at $48.84, representing a 318.12% increase over the past year. Despite its strong performance and "GREAT" financial health with a $7.23 billion market cap, InvestingPro suggests the stock might be overvalued. The company recently reported strong Q1 2026 earnings, exceeding expectations with an EPS of $0.50, and announced the acquisition of 34 skilled nursing facilities from Eduro Healthcare.
PACS Group Inc stock hits all-time high of 48.23 USD
PACS Group Inc. stock has reached an all-time high of $48.23, reflecting a significant 318.12% increase over the past year. Despite an InvestingPro analysis suggesting the stock may be overvalued, the company shows robust financial health with a $7.23 billion market cap, 15% revenue growth, and recent positive earnings, alongside a strategic acquisition of 34 skilled nursing facilities. Truist Securities maintains a Buy rating with a $52.00 price target due to strong operational execution and market trends.
PACS Group (PACS) Stock Climbs As Margins Strengthen And Risks Linger
PACS Group (PACS) stock climbed 1.9% after reporting strong Q2 2026 earnings, with net income up 50% and net margin improving to 4.8%. While the company shows solid operational progress and margin expansion, investors are weighing this against a P/E of 26.8x, ongoing legal issues, integration risks from rapid expansion, and internal control weaknesses. The article highlights both bull and bear cases for the company, noting the improvements in occupancy and skilled mix but also persistent concerns about execution and governance.
PACS renews M&A push, raises guidance as occupancy clears 90%
PACS Group is aggressively re-entering the acquisition market, buoyed by strong occupancy rates exceeding 90% and improved labor conditions. The company raised its full-year 2026 revenue guidance to $5.75 billion to $5.85 billion and adjusted EBITDA guidance to $640 million to $660 million after a robust Q2 performance. This renewed expansion comes as PACS celebrates operational successes across its 324 facilities, including high star ratings and stabilization in staffing costs.
PACS Group, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:PACS) 2026-08-05
PACS Group, Inc. released its Q2 2026 earnings call presentation, reporting an EPS of $0.63, beating estimates by $0.07. The company also announced revenue of $1.43 billion, surpassing expectations by $14.12 million and showing a 9.07% year-over-year increase. This presentation provides detailed insights into their financial performance for the quarter.
Avoiding Lag: Real-Time Signals in (PACS) Movement
This article analyzes Pacs Group Inc. (NASDAQ: PACS), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones, alongside multi-timeframe signal analysis for support and resistance levels. The analysis also emphasizes an exceptional risk-reward short setup.
Press Release: PACS Group, Inc. Reports Second Quarter 2026 Results
PACS Group, Inc. announced its financial results for the second quarter of 2026. The company reported its earnings, providing investors and stakeholders with an update on its performance and operational highlights for the period.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PACS Group
Faruqi & Faruqi, LLP is investigating potential claims against PACS Group, Inc. (NYSE: PACS) on behalf of investors who suffered losses exceeding $50,000. The investigation follows allegations that PACS Group engaged in a scheme to submit false Medicare claims, bill for unnecessary therapies, and falsify documentation related to licensure and staffing, which significantly impacted the company's operating and net income. Investors are reminded of the January 13, 2025 deadline to seek the role of lead plaintiff in the federal securities class action lawsuit.
Pacs Group Inc reports results for the quarter ended June 30 - Earnings Summary
Pacs Group Inc has released its earnings summary for the quarter that ended on June 30. The full article with detailed results is available for subscribers to TradingView, which aggregates news from various sources including Reuters.
PACS Group, Inc. Reports Second Quarter 2026 Results
PACS Group, Inc. reported strong second-quarter 2026 results, with revenue reaching $1.43 billion, a 9.1% increase year-over-year, and net income up 49.8% to $76.3 million. The company also announced an increased full-year 2026 Adjusted EBITDA guidance to $640 million-$660 million and revenue guidance to $5.75 billion-$5.85 billion, driven by continued strong performance and strategic acquisitions, including the ongoing integration of 34 facilities from Eduro Healthcare. Overall occupancy improved to 90.4%, significantly above the industry average.
Earnings Flash (PACS) PACS Group, Inc. Posts Q2 Adjusted EPS $0.63 per Share, vs. FactSet Est of $0.54
PACS Group, Inc. reported its Q2 adjusted EPS at $0.63 per share, surpassing FactSet's estimate of $0.54. This positive earnings surprise indicates stronger financial performance than anticipated for the quarter. The company also announced an increase in its earnings guidance for the fiscal year 2026.
PACS Group Q2 Revenue Rises 9 Percent to $1.43 Billion
PACS Group (PACS) reported a 9.1% increase in Q2 2026 revenue to $1.43 billion, with net income rising to $76.3 million. The company also raised its full-year 2026 revenue guidance to $5.75-$5.85 billion and adjusted EBITDA guidance to $640-$660 million. Insider trading data shows significant sales by executives, while institutional investors show mixed activity with some increasing and others decreasing their holdings.
PACS Group lifts 2026 adjusted EBITDA guidance to $640M-$660M
PACS Group, Inc. announced strong second-quarter 2026 results, with revenue up 9.1% to $1.43 billion and net income increasing 49.8% to $76.3 million. The company has raised its full-year 2026 Adjusted EBITDA guidance to $640 million-$660 million and revenue guidance to $5.75 billion-$5.85 billion, reflecting robust operational performance and strategic acquisitions. These results include contributions from recent acquisitions, notably 20 facilities from the Eduro transaction, with more expected to close later in the year.
PACS Group earnings in focus as post-acute healthcare tests momentum
PACS Group Inc. is reporting second-quarter earnings, with investors focusing on the company's ability to sustain its recovery amidst industry challenges in post-acute healthcare. Analysts anticipate a 31% jump in EPS from the prior year, with all six analysts rating the stock a Strong Buy. Key areas for investors include margin trends, occupancy and quality metrics, and capital deployment strategy, as the stock has seen a significant rally.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PACS Group
Faruqi & Faruqi, LLP is investigating potential claims against PACS Group, Inc. (NYSE: PACS) and encourages investors who suffered losses exceeding $50,000 to contact them. The investigation follows a federal securities class action alleging that PACS Group engaged in a scheme involving false Medicare claims, unnecessary therapies, and falsified documentation, which artificially inflated its operating and net income. A Hindenburg Research report and subsequent announcements by PACS Group regarding civil investigative demands led to significant drops in the company's share price.
Earnings To Watch: PACS Group Inc (PACS) Reports Q2 2025 Result
PACS Group Inc (NYSE:PACS) is slated to release its Q2 2025 earnings on August 4, 2026, with revenue estimated at $1414.87 million and earnings per share at $0.53. The company's revenue estimates for the full year 2025 have increased, while 2025 earnings estimates have slightly declined. In the prior quarter, PACS exceeded analyst expectations for both revenue and earnings, leading to a significant one-day stock increase.
Press Release: PACS Group Schedules Second Quarter 2026 Earnings Release and Conference Call
PACS Group, a post-acute healthcare provider, announced it will release its second quarter 2026 financial results after market close on Tuesday, August 13, 2026. A conference call and webcast will follow at 5:00 PM ET on the same day to discuss the results and business outlook.
Pacs Group Inc (PACS) Financial Health: Profitability & Balance Sheet Analysis
Pacs Group Inc (PACS) currently holds a financial score of 8.60, placing it 16th out of 75 companies in the Healthcare Providers & Services industry. The company's financial status is considered weak, despite having high operating efficiency. Key financial metrics such as cash and cash equivalents, total assets, total liabilities, and free cash flow have not yet been disclosed by the company.
PACS Group Schedules Second Quarter 2026 Earnings Release and Conference Call
PACS Group announced that it will release its financial results for the second quarter ended June 30, 2026, on Tuesday, August 4, 2026, after market close. Management will host a conference call on Wednesday, August 5, 2026, at 11:30 a.m. ET to discuss these results. The company encourages investors to regularly monitor its communication channels for material information.
PACS Group Q2 Results: Earnings Release and Call Scheduled
PACS Group, Inc. (NYSE: PACS) has announced its Q2 2026 financial results will be released on Tuesday, August 4, 2026, after market close. Following the release, management will host a conference call on Wednesday, August 5, 2026, at 11:30 a.m. ET to discuss the findings. The company, which operates 324 post-acute care facilities across 17 states, provides investor access to the call via webcast or telephone.
PACS|Pacs Group Inc|Price:47.050|Chg%:+0.200
This article provides a comprehensive stock analysis of Pacs Group Inc (PACS), highlighting its strong growth potential and stable fundamentals. While the stock is considered fairly valued and has high institutional ownership, technical indicators suggest a sideways trading pattern. The analysis includes detailed scores for financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk assessment, along with peer comparisons.
Is Media Scrutiny of Colorado Care Standards Altering The Investment Case For PACS Group (PACS)?
A recent investigation by The Denver Post into resident care at PACS Group's Colorado nursing homes raises questions about the company's care standards and reputation. While this scrutiny does not immediately alter the short-term catalysts like property integration, it highlights the importance of quality of care and regulatory compliance. Investors should consider how such media attention could interact with PACS Group's reliance on Medicaid quality incentives and its acquisition-heavy growth strategy.
